调强放疗 alone 对比同步放化疗在具有不良特征的II期和T3N0鼻咽癌患者中的疗效:一项倾向性评分匹配队列研究
该回顾性队列纳入287例具有不良因素的II期和T3N0鼻咽癌患者,其中98例接受单纯调强放疗,189例接受顺铂为基础的同步放化疗,经倾向性评分匹配后比较生存结局。中位随访90.8个月,两组所有生存终点均无显著差异,但单纯调强放疗组急性毒性发生率显著低于同步放化疗组。
要点
- 倾向性评分匹配后,单纯调强放疗与同步放化疗在5年无失败生存、总生存、无远处转移生存和无局部区域复发生存上均无显著差异。
- 单纯调强放疗组急性毒性发生率显著低于同步放化疗组。
- 对于合并非单一不良因素的患者,综合治疗策略需进一步探索。
核心结论
- 在采用调强放疗的具有不良因素的II期和T3N0鼻咽癌患者中,加用同步化疗未带来生存获益,但急性毒性发生率显著增加。
- 对于合并非单一不良因素的患者,综合治疗策略需进一步探索。
研究设计与样本
- 回顾性分析287例具有不良因素的II期和T3N0鼻咽癌患者,其中98例接受单纯调强放疗(单纯IMRT组),189例接受顺铂为基础的同步放化疗(CCRT组)。
- 采用倾向性评分匹配(PSM)平衡可能的预后因素,使用Kaplan-Meier法评估生存率,log-rank检验比较组间差异。
主要发现
- 中位随访时间为90.8个月(四分位距=75.6-114.7个月)。
- 单纯IMRT组与CCRT组匹配良好,但所有生存相关终点均无显著差异:5年无失败生存率84.3% vs 82.7%(P=0.68);5年总生存率87.3% vs 90.6%(P=0.11);5年无远处转移生存率92.8% vs 92.5%(P=0.97);5年无局部区域复发生存率93.4% vs 89.9%(P=0.30)。
- 单纯IMRT组急性毒性发生率显著低于CCRT组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Whether concurrent chemoradiotherapy would provide survival benefits in patients with stage II and T3N0 NPC with adverse factors remains unclear in IMRT era. We aimed to assess the value of concurrent chemotherapy compared to IMRT alone in stage II and T3N0 NPC with adverse features. MATERIALS AND METHODS: 287 patients with stage II and T3N0 NPC with adverse factors were retrospectively analyzed, including 98 patients who received IMRT alone (IMRT alone group) and 189 patients who received cisplatin-based concurrent chemotherapy (CCRT group). The possible prognostic factors were balanced using propensity score matching (PSM). Kaplan-Meier analysis was used to evaluate the survival rates, and log-rank tests were employed to compare differences between groups. RESULTS: The median follow-up duration was 90.8 months (interquartile range = 75.6-114.7 months). The IMRT alone and the CCRT group were well matched; however, for all survival-related endpoints, there were no significant differences between them (5-year failure-free survival: 84.3% vs. 82.7%, P value = 0.68; 5-year overall survival: 87.3% vs. 90.6%, P value = 0.11; 5-year distant metastasis-free survival: 92.8% vs. 92.5%, P value = 0.97; 5-year locoregional relapse-free survival: 93.4% vs. 89.9%, P value = 0.30). The incidence of acute toxicities in the IMRT alone group was significantly lower than that in the CCRT group. CONCLUSION: For patients with stage II and T3N0 NPC with adverse features treated using IMRT, no improvement in survival was gained by adding concurrent chemotherapy; however, the occurrence of acute toxicities increased significantly. For those combined with non-single adverse factors, the comprehensive treatment strategy needs further exploration.
引用
- Zhang WW, Lin JY, Wang GY, et al. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study. Radiother Oncol. 2024. PMID: 38432309. doi:10.1016/j.radonc.2024.110189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。